← Back to Search

Mindfulness Meditation

Internet-Based Webinars for Chronic Myelogenous Leukemia

N/A

Waitlist Available

Led By Kelly Schoenbeck, MD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

CAREGIVER: Be able to speak and read English

PATIENT: Carry a diagnosis of BCR-ABL-negative MPN or CML

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 4 weeks, and 8 weeks, up to 8 weeks total

Awards & highlights

Study Summary

This trial looks at how well a distress reduction intervention, called "Being Present", works to improve the quality of life of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs) or chronic phase chronic myeloid leukemia (CP-CML) who are taking tyrosine kinase inhibitors (TKIs) and their caregivers.

Eligible Conditions

Myeloproliferative Neoplasms
Chronic Myelogenous Leukemia
Leukemia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 4 weeks, and 8 weeks, up to 8 weeks total

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 4 weeks, and 8 weeks, up to 8 weeks total

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 weeks, and 8 weeks, up to 8 weeks total for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Duration of playing recorded webinars

Frequency of Attrition Causes

Frequency of Attrition over time

+11 more

Secondary outcome measures

Malignant Neoplasms

Mean change in scores on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Mean change in scores on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CML24)

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Being Present (Supportive Care)Experimental Treatment2 Interventions

Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Online Mindfulness Meditation

2020

N/A

~120

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,502 Previous Clinical Trials

15,236,588 Total Patients Enrolled

American Society of HematologyOTHER

11 Previous Clinical Trials

20,811 Total Patients Enrolled

Kelly Schoenbeck, MDPrincipal InvestigatorUniversity of California, San Francisco

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have consented to enter into this research study?

"Affirmative. Clinicaltrials.gov documents that this clinical trial, which was initially posted on October 22nd 2020, is currently in search of participants. Approximately 100 individuals need to be gathered from 1 research centre."

Answered by AI

What key goals is this trial attempting to accomplish?

"This medical trial will measure its primary outcome, the Frequency of Participants' Perception of web-based mindfulness meditation, across a time frame not exceeding 90 days. Secondary outcomes consist of assessing mean changes in scores from validated surveys such as the Five Facet Mindfulness Questionnaire Short Form (FFMQ-SF), National Comprehensive Cancer Network (NCCN) Distress Thermometer scores and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). These all range between 0 to 100 with higher score representing either healthier function or greater symptomatology."

Answered by AI

Are there any opportunities for participation in this experiment currently available?

"Affirmative. As indicated on clinicaltrials.gov, this medical examination is currently searching for participants. The trial was first made public on October 22nd 2020 and has been recently modified as of August 9th 2022; 100 volunteers are sought from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

2020. "A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04605211.